The U.S. Army Medical Research and Development Command has announced a Broad Agency Announcement (BAA) for extramural medical research funding, which will be open from October 1, 2022, to September 30, 2027. The BAA focuses on various military medical research programs, including those for infectious diseases, combat casualty care, operational medicine, and medical defense against biological and chemical threats, emphasizing innovation in research proposals that benefit both military and civilian health. Interested applicants are required to submit pre-proposals through eBRAP, follow up with full proposals via Grants.gov, and adhere to specific guidelines pertaining to funding mechanisms, proposal content, and review processes.
The FY23-FY27 Department of Defense (DOD) Broad Agency Announcement (BAA) for Extramural Medical Research, issued by the U.S. Army Medical Research and Development Command (USAMRDC), invites proposals for innovative research projects to enhance military and civilian healthcare. This solicitation, valid from October 1, 2022, to September 30, 2027, is continuously open and encourages applications related to three key areas: Military Infectious Diseases, Combat Casualty Care, and Military Operational Medicine. Applicants must follow specific submission guidelines through Grants.gov and eBRAP, ensuring their proposals align with DOD objectives.
This BAA emphasizes the need for basic and applied research aimed at improving medical solutions for the Armed Forces and the general public, highlighting the competitive nature of the selection process due to anticipated high-quality submissions and limited funding availability. It outlines the eligibility criteria for organizations, emphasizes the importance of collaboration with military and VA resources, and details the requirements for clinical trials and data sharing. The USAMRDC seeks innovative approaches that enhance readiness and performance while ensuring that all proposals are ethically sound and comply with regulatory standards.